Jefferies initiates coverage on Stemline Therapeutics (NASDAQ: STML) with a Buy rating and $60 price target, suggesting 77% upside.

This article: 128 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE